Recent Updates
Recently added Catalysts
TLX Negative Sentiment Score: 20/100

Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – TLX

Key Takeaway: Telix Pharmaceuticals Limited is under scrutiny following a class action lawsuit filed by the DJS Law Group for alleged violations of securities laws. The lawsuit claims that Telix made false and misleading statements about its progress in developing prostate cancer treatments and the robustness of its supply chain. Shareholders who purchased shares between February 21, 2025, and August 28, 2025, are being urged to join the case to seek recovery for their losses. The case highlights concerns over the company's transparency and investor trust.

Market Sentiment Analysis

CONCERNS & RISKS

  • Telix Pharmaceuticals is facing a class action lawsuit for potentially violating securities laws.
  • The company allegedly made false and misleading statements regarding its prostate cancer treatment development.
  • Investors have been encouraged to contact a law firm regarding losses incurred during a specific class period.

Full Press Release Details

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 21, 2025 to August 28, 2025
DEADLINE: January 9, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Telix overstated its progress in developing and commercializing prostate cancer treatments. The Company also overstated the strength of its supply chain. Based on these facts, Telix’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What is the class action lawsuit against Telix Pharmaceuticals?

The lawsuit alleges Telix made false statements about its prostate cancer treatments and supply chain.

What is the class period for the Telix lawsuit?

The class period is from February 21, 2025, to August 28, 2025.

When is the deadline to join the class action?

The deadline to join the class action is January 9, 2026.

Do I need to be a lead plaintiff to recover losses?

No, you do not need to be a lead plaintiff to participate in any recovery.

How can shareholders stay updated on the lawsuit?

Shareholders will receive updates through a portfolio monitoring software upon registration.

Last updated: Nov 17, 2025